Literature DB >> 19100302

Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect.

Shuxia Song1, Chunyan Liu, Junxia Wang, Yan Zhang, Hongyu You, Yue Wang, Fuying Liu, Shuhan Sun.   

Abstract

With accumulating evidence indicating the importance of cytotoxic T lymphocytes (CTLs) in the antitumor response, strategies are being pursued to elicit augmented CD8(+) T-cell responses against tumors with tumor vaccines. Here, we report the protective efficacy of vaccine-elicited antitumor immune responses with an aggressive HBc-expressing B16-HBc melanoma, which expressed HBc as a self and model antigen, tumor model. We demonstrated that the significantly better memory responses or marked inhibition on tumor growth could be achieved after coadministration of cytokine adjuvants RANTES and Flt3L in a DNA prime-protein boost regimen. Furthermore, the augmentation of DNA prime-protein boost regimens by cytokines gene was due to the improvement the immunopotency of DNA vaccine and subsequently the augmented Ag-specific and IFN-gamma mediating CD8(+) T-cell responses after protein boosting. Hence, this study demonstrates for the first time that combinatorial use of chemotactic and potent DC-specific growth factor molecules provides a useful strategy for enhancing antitumor responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100302     DOI: 10.1016/j.vaccine.2008.11.095

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.

Authors:  T Nguyen-Hoai; M Pham-Duc; M Gries; B Dörken; A Pezzutto; J Westermann
Journal:  Cancer Gene Ther       Date:  2016-04-08       Impact factor: 5.987

Review 2.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

3.  Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Authors:  Zachary Barnard; Hiroaki Wakimoto; Cecile Zaupa; Anoop P Patel; Jacquelyn Klehm; Robert L Martuza; Samuel D Rabkin; William T Curry
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

Review 4.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

5.  Reduced tumourigenicity of EG7 after RANTES gene transfer and the underlying mechanism.

Authors:  Jiuzhou Li; Huiling Diao; Dongmei Zhao; Jianbin Zhang
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

6.  Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.

Authors:  Amy Haseley Thorne; Kirsten N Malo; Ashley J Wong; Tricia T Nguyen; Neil Cooch; Charles Reed; Jian Yan; Kate E Broderick; Trevor R F Smith; Emma L Masteller; Laurent Humeau
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

7.  Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways.

Authors:  G Luca Gusella; Avelino Teixeira; Judith Aberg; Vladimir N Uversky; Arevik Mosoian
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.